[go: up one dir, main page]

BR0211296A - Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado - Google Patents

Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado

Info

Publication number
BR0211296A
BR0211296A BR0211296-5A BR0211296A BR0211296A BR 0211296 A BR0211296 A BR 0211296A BR 0211296 A BR0211296 A BR 0211296A BR 0211296 A BR0211296 A BR 0211296A
Authority
BR
Brazil
Prior art keywords
immunogenic peptide
subgroup
polyclonal
conjugate
nucleic acid
Prior art date
Application number
BR0211296-5A
Other languages
English (en)
Inventor
Nathalie Corvaia
Thien Nguyen Ngoc
Alain Beck
Hel Ne Plotnicky
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR0211296A publication Critical patent/BR0211296A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PEPTìDEO IMUNOGêNICO DERIVADO DA PROTEìNA G DO VRS DO SUB-GRUPO A OU B, SEQuêNCIA DE áCIDO NUCLEICO, COMPOSIçãO FARMACêUTICA, ANTICORPOS POLICLONAIS OU MONOCLONAIS, KIT DE DIAGNóSTICO, UTILIZAçãO DE UM PEPTìDEO IMUNOGêNICO, E, CONJUGADO". A presente invenção refere-se a novos peptídeos imunogênicos derivados da proteína G de VRS de sub-grupo A ou B compreendendo pelo menos: um primeiro peptídeo derivado da proteína G de VRS de sub-grupo A ou B compreendendo pelo menos em posição 173, 176, 182 e 186, uma cisteína, e cuja extremidade C-terminal compreende, no máximo, o aminoácido em posição 192; e um segundo peptídeo derivado de uma proteína de VRS de sub-grupo A ou B, o referido segundo peptídeo estando situado a jusante do referido primeiro peptídeo, de modo que o peptídeo imunogênico produzido apresenta uma ponte dissulfeto ligando os resíduos 173 e 186 e uma segunda ponte dissulfeto ligando os resíduos 176 e 182.
BR0211296-5A 2001-07-20 2002-07-19 Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado BR0211296A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0109731A FR2827605B1 (fr) 2001-07-20 2001-07-20 Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
PCT/FR2002/002599 WO2003010317A1 (fr) 2001-07-20 2002-07-19 Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin

Publications (1)

Publication Number Publication Date
BR0211296A true BR0211296A (pt) 2004-09-14

Family

ID=8865750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211296-5A BR0211296A (pt) 2001-07-20 2002-07-19 Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado

Country Status (16)

Country Link
US (3) US7309494B2 (pt)
EP (1) EP1409692B1 (pt)
JP (1) JP4310184B2 (pt)
CN (1) CN1556857A (pt)
AT (1) ATE408696T1 (pt)
AU (1) AU2002336148B8 (pt)
BR (1) BR0211296A (pt)
CA (1) CA2455360A1 (pt)
DE (1) DE60228971D1 (pt)
DK (1) DK1409692T3 (pt)
ES (1) ES2314102T3 (pt)
FR (1) FR2827605B1 (pt)
MX (1) MXPA04000597A (pt)
PT (1) PT1409692E (pt)
WO (1) WO2003010317A1 (pt)
ZA (1) ZA200400916B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426312C (en) 2000-10-18 2014-01-14 Ralph A. Tripp Compositions and methods for modulating rsv infection and immunity
EP1768993A4 (en) * 2004-06-16 2008-07-23 Univ Johns Hopkins CYSTIC REGION OF HUMAN RESPIRATORY SYNZYTIAL VIRUS AND METHOD OF USE THEREOF
EP1972348A1 (en) * 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
KR20110061611A (ko) 2008-09-18 2011-06-09 노파르티스 아게 백신 보조제 조합
WO2011017442A2 (en) * 2009-08-04 2011-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Anti-rsv immunogens and methods of immunization
JP2013503148A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
NZ598654A (en) 2009-09-02 2014-05-30 Novartis Ag Immunogenic compositions including tlr activity modulators
JP5806233B2 (ja) * 2009-12-21 2015-11-10 コーネル ユニバーシティＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ 新規ニューモウィルス組成物及びその使用方法
WO2012031140A1 (en) 2010-09-01 2012-03-08 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
EP2652511B8 (en) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Flow cytometry analysis of materials adsorbed to metal salts
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
US10059746B2 (en) 2011-04-04 2018-08-28 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
ES2395677B1 (es) * 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
JP6325986B2 (ja) 2012-03-07 2018-05-16 ノバルティス アーゲー 免疫学的に有用なアルギニン塩
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
NZ704005A (en) 2012-08-01 2016-07-29 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
CN105085684B (zh) * 2014-05-14 2020-04-17 上海亨臻实业有限公司 Pcsk9靶向重组疫苗设计及其应用
US10744193B2 (en) * 2015-03-30 2020-08-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic RSV polypeptides
BR112018016648A2 (pt) * 2016-02-16 2018-12-26 The University Of Queensland peptídeos alfa-conotoxina
CN109232737A (zh) * 2016-03-01 2019-01-18 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
US20220411783A1 (en) * 2018-10-12 2022-12-29 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
CA3130433A1 (en) 2019-02-28 2020-09-03 Km Biologics Co., Ltd. Rsv f/g chimeric vaccine
US11360877B2 (en) * 2020-09-14 2022-06-14 International Business Machines Corporation Forming microservices from monolithic applications
WO2024084785A1 (ja) * 2022-10-20 2024-04-25 一般財団法人阪大微生物病研究会 Ｒｓウイルスワクチンとしての利用に好適な組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689622T2 (de) 1986-01-14 1994-06-16 Univ North Carolina Impfstoffe gegen menschliche respiratorische viren.
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AUPO026596A0 (en) 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
FR2766192B1 (fr) 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
FR2776521B1 (fr) 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale

Also Published As

Publication number Publication date
AU2002336148B2 (en) 2007-12-13
AU2002336148B8 (en) 2008-06-19
US7309494B2 (en) 2007-12-18
US7524627B2 (en) 2009-04-28
WO2003010317A1 (fr) 2003-02-06
US20090036367A1 (en) 2009-02-05
ATE408696T1 (de) 2008-10-15
FR2827605A1 (fr) 2003-01-24
JP2005511010A (ja) 2005-04-28
DK1409692T3 (da) 2009-02-02
DE60228971D1 (de) 2008-10-30
ES2314102T3 (es) 2009-03-16
EP1409692B1 (fr) 2008-09-17
FR2827605B1 (fr) 2004-07-16
CN1556857A (zh) 2004-12-22
JP4310184B2 (ja) 2009-08-05
CA2455360A1 (fr) 2003-02-06
PT1409692E (pt) 2008-12-26
MXPA04000597A (es) 2004-04-20
EP1409692A1 (fr) 2004-04-21
ZA200400916B (en) 2004-08-25
US20040175395A1 (en) 2004-09-09
US20090181042A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
IS7601A (is) Neisser-bóluefnasamsetningar sem innihalda blönduaf mótefnavökvum
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
NL300897I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit
BRPI0412245A (pt) anticorpos de rg1 e usos destes
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
HUP0400313A2 (hu) Új, biotechnológiai úton előállított, humán terápiára alkalmas szuperantigének
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
DE69609188D1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
ATE542829T1 (de) Impfstoff
PE20071055A1 (es) Anticuerpos anti mn
EA201170353A1 (ru) Антитела против гепатита с и их применение
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
WO2006034292A3 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
HUP0303134A2 (hu) HIV-peptidek, antigének, vakcinakészítmények, immunológiai mérési reagenskészletek és eljárás HIV által indukált antitestek detektálására
ATE419872T1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
WO2010044889A3 (en) Torque teno virus (ttv) isolates and compositions
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
ATE425187T1 (de) Materialien und methoden zur behandlung von hepatitis c
WO2022020636A3 (en) Immunogens derived from sars-cov2 spike protein
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.